Ace Blend Raises $9.9 Mn Series A2 to Fund Clinical Trials

Ace Blend, an Indian direct-to-consumer nutrition and dietary supplements brand, has raised $9.9 million (about ₹95 crore) in a Series A2 round led by 3one4 Capital. Existing investor Fireside Ventures also participated.

The startup says the money will go towards clinical trials, supply chain improvements, research and development, and new nutrition formats.

Science and testing first

Founder and CEO Shivam Hingorani said the trials will be run by credible contract research organisations and are meant to be published in peer-reviewed international journals. The company also plans shelf-stability studies at launch and six months later, which Hingorani said would build long-term safety data.

A third priority is an automated testing system that checks each batch for nutritional accuracy, pesticide residues and heavy metals without human intervention. "Trust is not enough" in the supplements market, Hingorani said, arguing that product claims need scientific evidence.

Business and product plans

Founded in 2018 by Hingorani, with Saif Mehkri joining as cofounder in 2022, Ace Blend sells around 14 SKUs covering heart health, brain health, sleep, recovery, gut health, strength and immunity. They include plant-based protein powders and superfood mixes. Its own website generates about 50% of revenue, and the rest comes from marketplaces such as Amazon and Flipkart and quick commerce platforms such as Zepto and Blinkit.

Hingorani said the company grew 300% in FY26 and has a repeat purchase rate of nearly 48%. It is targeting annual recurring revenue of ₹250-300 crore over the next 12-18 months, with profitability in sight.

New products in development include a formulation created with a gut-health specialist to address leaky gut, a natural-nutrient blend meant to lower inflammation, an eye-health product and a fibre-based gut-health format.

The round comes as India's supplements market expands. Grand View Research valued it at $5.8 billion in 2025 and projects $6.6 billion in 2026 and $12.4 billion by 2033, a CAGR of 9.5%. Earlier this month, D2C brand The Stack raised ₹21.5 crore for a similar push into R&D and range expansion.